<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601847</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL109293</org_study_id>
    <secondary_id>R01HL109293</secondary_id>
    <nct_id>NCT01601847</nct_id>
  </id_info>
  <brief_title>Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy</brief_title>
  <acronym>D-Wheeze</acronym>
  <official_title>Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Western Reserve University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to identify a vitamin D supplementation strategy that best promotes
      the lung, immune, and overall health of black infants born preterm (28-36 weeks gestational
      age). This is a high risk population that seems to have unique vitamin D needs, and
      inappropriate supplementation may promote wheezing or allergy. The results of this study will
      help form nutritional recommendations for the approximately 100,000 black infants born at
      30-36 weeks gestational age in the U.S. every year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Black infants face the highest rates of prematurity in the U.S. (18%), have high rates of
      prematurity-associated wheezing illnesses, and tend to have lower vitamin D levels. The goal
      of this [comparative effectiveness] study is to identify a vit. D supplementation strategy
      that minimizes recurrent wheezing in infancy. Long recognized as important for bone health, a
      growing body of evidence suggests that vit. D may play a role in the regulation and
      development of many organ systems. The D pathway regulates lung inflammation and impacts
      morphogenesis, structure, and cell growth and survival in bronchial smooth muscle. Vit. D
      exposure has the potential to skew cytokine expression from a Th1 (less allergic) to a Th2
      (more allergic) phenotype. Due to their developmental immaturity, preterm infants may be
      particularly vulnerable to any positive or negative effects of vit. D supplementation on the
      lung, airway, and immune system. Our preliminary data, supported by the literature, suggests
      that overly aggressive vit. D supplementation may inadvertently increase wheezing in infancy
      in black, but not white, preterm infants; however, vit. D deficiency could theoretically also
      increase wheezing via vulnerability to respiratory pathogens. The proposed study is a
      randomized clinical trial comparing the effect of two different enteral vitamin D
      supplementation strategies on recurrent wheezing in infancy in 300 black infants born preterm
      at 28 0/7-36 6/7 wks gestational age, a population for whom neither vit. D requirements nor
      optimal vit. D serum levels have been established. The investigators will test two
      strategies: (I) sustained supplementation until 6 mo. of age adjusted for prematurity, and
      (II) cessation of supplementation when a minimum dietary intake of 200 IU/day is reached. The
      specific aims are to characterize the effect of each strategy on (aim 1) recurrent wheezing
      and (aim 2) allergic sensitization and atopy. The investigators will (aim 3) explore the
      relationship between vit. D serum levels and recurrent wheezing. The investigators
      hypothesize that strategy II will be more effective in promoting pulmonary health by
      minimizing recurrent wheezing, allergic sensitization, and overall healthcare utilization,
      and will be sufficient to prevent clinical vit. D deficiency. The investigators also
      hypothesize that optimal vit. D serum levels will be lower than the norms for other
      populations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 12, 2017</completion_date>
  <primary_completion_date type="Actual">March 12, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Infants With Recurrent Wheezing</measure>
    <time_frame>up to 12 months adjusted age</time_frame>
    <description>Recurrent wheezing was defined as more than 1 episode of wheezing reported during the study period. Separate episodes were defined as occurring at least 2 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number With Infants With Allergic Sensitization as Measured by the PhadiaTop Infant Assay</measure>
    <time_frame>Measured at the 12 month adjusted age visit</time_frame>
    <description>Measured using the Phadiatop Infant IgE panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Density</measure>
    <time_frame>Measured at the 12 month adjusted age visit</time_frame>
    <description>Measured by bone speed of sound (ultrasound)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Wheezing</condition>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Sustained</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet-Limited</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity</description>
    <arm_group_label>Diet-Limited</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity</description>
    <arm_group_label>Sustained</arm_group_label>
    <other_name>D-Vi-Sol</other_name>
    <other_name>Vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. 28 0/7-36 6/7 weeks gestational age (GA) at birth;

          2. family identifies the child as black or African American;

          3. &lt; 28 days of supplemental oxygen (subsequent oxygen therapy for &lt; 72 hrs for a brief
             subsequent illness or surgery will be allowed);

          4. admitted to a participating site NICU, special care nursery, transitional care
             nursery, or well-baby nursery as a neonate; and

          5. &lt; 40 weeks corrected GA at enrollment.

        Exclusion criteria:

          1. BPD (&gt; 28 days of supplemental oxygen);

          2. pre-existing diagnosis of moderate to severe osteopenia of prematurity and/or alkaline
             phosphatase &gt; 700;

          3. history of fracture;

          4. gastrointestinal surgery, including for NEC;

          5. known gastrointestinal malabsorption;

          6. major congenital anomaly;

          7. congenital pulmonary or airway disorder (e.g., cystic fibrosis, tracheomalacia,
             swallowing disorder, bronchopulmonary sequestration);

          8. documented wheezing or stridor prior to enrollment;

          9. previous vit. D supplementation with &gt; 400 IU/day;

         10. family plans to move more than 60 miles from CWRU or other pre-defined radius at other
             sites;

         11. baseline hypo- or hypercalcemia, hypo- or hyperphosphatemia; and

         12. baseline 25(OH) D level &lt; 10 ng/ml.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Maria Hibbs, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <results_first_submitted>March 11, 2018</results_first_submitted>
  <results_first_submitted_qc>May 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2018</results_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Case Western Reserve University</investigator_affiliation>
    <investigator_full_name>Anna Maria Hibbs</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 19, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT01601847/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants were recruited from participating NICUs, special care nurseries, and well-baby nurseries.</recruitment_details>
      <pre_assignment_details>If all eligibility labs were not available from routine clinical care, parents were consented prior to obtaining the remaining eligibility labs. If those post-consent laboratory results made the infant ineligible, they were not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sustained</title>
          <description>Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
Cholecalciferol: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
        </group>
        <group group_id="P2">
          <title>Diet-Limited</title>
          <description>Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
Cholecalciferol: Once the dietary intake of vitamin D has exceeded 200 IU/Day from formula or fortifiers, the infants will receive placebo until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One infant was withdrawn from the study prior to completion of the baseline questionnaire a data collection, and is not included all rows in this table.</population>
      <group_list>
        <group group_id="B1">
          <title>Sustained</title>
          <description>Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
Cholecalciferol: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
        </group>
        <group group_id="B2">
          <title>Diet-Limited</title>
          <description>Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
Cholecalciferol: Once the dietary intake of vitamin D has exceeded 200 IU/Day from formula or fortifiers, the infants will receive placebo until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="147"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>One infant withdrew before completion of all baseline data forms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at birth</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.00" lower_limit="29.14" upper_limit="36.86"/>
                    <measurement group_id="B2" value="33.50" lower_limit="28.00" upper_limit="36.86"/>
                    <measurement group_id="B3" value="33.14" lower_limit="28.00" upper_limit="36.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth weight</title>
          <population>One infant was withdrawn before all baseline/inpatient data capture forms were completed.</population>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.84" lower_limit="0.82" upper_limit="4.05"/>
                    <measurement group_id="B2" value="1.96" lower_limit="0.79" upper_limit="3.62"/>
                    <measurement group_id="B3" value="1.87" lower_limit="0.79" upper_limit="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple birth (twins and triplets)</title>
          <population>Measure Analysis Population Description: One infant withdrew before completion of all baseline data forms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antenatal steroids</title>
          <population>Measure Analysis Population Description: One infant withdrew before completion of all baseline data forms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of ventilator support</title>
          <population>Measure Analysis Population Description: One infant withdrew before completion of all baseline data forms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of oxygen administration</title>
          <population>Measure Analysis Population Description: One infant withdrew before completion of all baseline data forms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Receiving maternal breast milk at randomization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Discharge season (Oct-March)</title>
          <population>Measure Analysis Population Description: One infant withdrew before completion of all baseline data forms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calcium (mg/dl)</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" lower_limit="7.2" upper_limit="10.8"/>
                    <measurement group_id="B2" value="9.5" lower_limit="7.1" upper_limit="10.7"/>
                    <measurement group_id="B3" value="9.5" lower_limit="7.1" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Phosphorus (mg/dl)</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" lower_limit="3.5" upper_limit="8.9"/>
                    <measurement group_id="B2" value="6.9" lower_limit="3.6" upper_limit="8.9"/>
                    <measurement group_id="B3" value="7.0" lower_limit="3.5" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline phosphatase (U/L)</title>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268" lower_limit="128" upper_limit="686"/>
                    <measurement group_id="B2" value="257" lower_limit="70" upper_limit="563"/>
                    <measurement group_id="B3" value="263" lower_limit="70" upper_limit="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total circulating 25(OH)D (ng/ml)</title>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="147"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.1" lower_limit="10.0" upper_limit="71.0"/>
                    <measurement group_id="B2" value="21.0" lower_limit="10.0" upper_limit="50.0"/>
                    <measurement group_id="B3" value="20.2" lower_limit="10.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Infants With Recurrent Wheezing</title>
        <description>Recurrent wheezing was defined as more than 1 episode of wheezing reported during the study period. Separate episodes were defined as occurring at least 2 weeks apart.</description>
        <time_frame>up to 12 months adjusted age</time_frame>
        <population>Infants that were withdrawn, completely lost to follow-up, who died, or for whom recurrent wheezing status was indeterminate due to a missing 12 month visit (n=8) were not included in the primary analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sustained</title>
            <description>Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
Cholecalciferol: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Diet-Limited</title>
            <description>Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
Cholecalciferol: Once the dietary intake of vitamin D has exceeded 200 IU/Day from formula or fortifiers, the infants will receive placebo until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Recurrent Wheezing</title>
          <description>Recurrent wheezing was defined as more than 1 episode of wheezing reported during the study period. Separate episodes were defined as occurring at least 2 weeks apart.</description>
          <population>Infants that were withdrawn, completely lost to follow-up, who died, or for whom recurrent wheezing status was indeterminate due to a missing 12 month visit (n=8) were not included in the primary analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Poisson</method>
            <method_desc>Poisson regression using GEE with robust variance estimation (e.g. Zou, American Journal Epidemiology, 2004)</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0185</p_value>
            <method>logistic regression with GEE</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.522</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.304</ci_lower_limit>
            <ci_upper_limit>0.897</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number With Infants With Allergic Sensitization as Measured by the PhadiaTop Infant Assay</title>
        <description>Measured using the Phadiatop Infant IgE panel</description>
        <time_frame>Measured at the 12 month adjusted age visit</time_frame>
        <population>Positive result is &gt;0.35 U/L PAU/l</population>
        <group_list>
          <group group_id="O1">
            <title>Sustained</title>
            <description>Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
Cholecalciferol: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Diet-Limited</title>
            <description>Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
Cholecalciferol: Once the dietary intake of vitamin D has exceeded 200 IU/Day from formula or fortifiers, the infants will receive placebo until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number With Infants With Allergic Sensitization as Measured by the PhadiaTop Infant Assay</title>
          <description>Measured using the Phadiatop Infant IgE panel</description>
          <population>Positive result is &gt;0.35 U/L PAU/l</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For secondary outcomes, GEE is used to assess randomization arm association.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.228</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Density</title>
        <description>Measured by bone speed of sound (ultrasound)</description>
        <time_frame>Measured at the 12 month adjusted age visit</time_frame>
        <population>Bone density was not performed if (1) infant could not come to the clinic for their 12 month visit and the visit was done in the home (2) they missed their 12 month visit (3) the ultrasound was under repair, or (4) infant could not participate with the ultrasound to get a sufficient quality reading.</population>
        <group_list>
          <group group_id="O1">
            <title>Sustained</title>
            <description>Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
Cholecalciferol: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Diet-Limited</title>
            <description>Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
Cholecalciferol: Once the dietary intake of vitamin D has exceeded 200 IU/Day from formula or fortifiers, the infants will receive placebo until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Density</title>
          <description>Measured by bone speed of sound (ultrasound)</description>
          <population>Bone density was not performed if (1) infant could not come to the clinic for their 12 month visit and the visit was done in the home (2) they missed their 12 month visit (3) the ultrasound was under repair, or (4) infant could not participate with the ultrasound to get a sufficient quality reading.</population>
          <units>m/s</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3155" lower_limit="2908" upper_limit="3409"/>
                    <measurement group_id="O2" value="3149" lower_limit="2898" upper_limit="3351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.798</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 months adjusted age</time_frame>
      <desc>Study personnel screened for adverse events at each study visit. Adverse event categories/organ systems are not mutually exclusive (for instance, an AE could be coded under both respiratory and infectious categories). All significant associated symptoms/findings were coded for each (S)AE.
36 patients in the Sustained arm had a total of 44 SAEs; 38 patients in the Diet-Limited arm had a total of 56 SAEs. Some patients experienced more than one SAE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sustained</title>
          <description>Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
Cholecalciferol: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
        </group>
        <group group_id="E2">
          <title>Diet-Limited</title>
          <description>Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
Cholecalciferol: Once the dietary intake of vitamin D has exceeded 200 IU/Day from formula or fortifiers, the infants will receive placebo until they are 6 months of age adjusted for prematurity.
Exclusively breastfed infants receive 400 IU of vitamin D daily as needed beyond 6 months adjusted age for the duration of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diarrhea, non-infectious</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Vomiting, non-infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>GI, not otherwise specified</sub_title>
                <description>This category was coded if the condition did not fit into the other pre-specified GI categories</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Other (not classified elsewhere)</sub_title>
                <description>This category was coded if the important signs or symptoms related to the event were was not otherwise described by other pre-existing categories.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E2" events="27" subjects_affected="18" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>GI infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Other Infection</sub_title>
                <description>This category was coded if the infection was not described by other pre-specified infection categories.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture (bone)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Neurologic, not otherwise specified</sub_title>
                <description>This category was coded if the condition was not described by another pre-existing neurologic category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma or Wheezing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulmonary, not otherwise specified</sub_title>
                <description>This category was coded if the event did not fit in the other pre-specified pulmonary categories for infections, wheezing, or apnea.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>ALTE or BRUE</sub_title>
                <description>&quot;Apparent Life Threatening Event&quot; or &quot;Brief Resolved Unexplained Event.&quot; The American Academy of Pediatrics preferred terminology changed during the study.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated alkaline phosphatase</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="153"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diarrhea, non-infectious</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Vomiting, non-infectious</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>GI, not otherwise specified</sub_title>
                <description>This category was coded if the event was not described by the other GI categories.</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other AE</sub_title>
                <description>This category was coded if the relevant signs/symptoms of the AE were not otherwise captured by other categories.</description>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="153"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="163" subjects_affected="84" subjects_at_risk="153"/>
                <counts group_id="E2" events="155" subjects_affected="78" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Infection</sub_title>
                <counts group_id="E1" events="39" subjects_affected="27" subjects_at_risk="153"/>
                <counts group_id="E2" events="31" subjects_affected="23" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>GI Infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Infection, not otherwise specified</sub_title>
                <description>This category was coded if the event was not described by another infection category.</description>
                <counts group_id="E1" events="63" subjects_affected="44" subjects_at_risk="153"/>
                <counts group_id="E2" events="68" subjects_affected="51" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma or Wheezing</sub_title>
                <counts group_id="E1" events="65" subjects_affected="38" subjects_at_risk="153"/>
                <counts group_id="E2" events="60" subjects_affected="36" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="47" subjects_affected="36" subjects_at_risk="153"/>
                <counts group_id="E2" events="56" subjects_affected="42" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anna Maria Hibbs</name_or_title>
      <organization>Case Western Reserve University</organization>
      <phone>216-844-3387</phone>
      <email>annamaria.hibbs@cwru.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

